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Abstract
Hypertension  among people  with  chronic  kidney  disease  is  highly  prevalent  and
remains often poorly controlled. To adequately control blood pressure (BP), a combi‐
nation antihypertensive drug therapy is often required. The choice of the appropriate
antihypertensive regimen should be individualized according to the patient clinical
characteristics, the severity of chronic kidney disease (CKD), the levels at which BP
should be targeted and the presence or absence of proteinuria. In proteinuric CKD, solid
evidence from large‐scaled randomized trials suggest that agents blocking the renin‐
angiotensin‐aldosterone system (RAAS) should be the antihypertensive therapy of first
choice, given their superiority over the other antihypertensive drug classes in reducing
proteinuria and delaying nephropathy progression to end‐stage‐renal‐disease (ESRD).
In contrast, inhibition of the RAAS is shown to have no additional benefits towards
renoprotection in people with non‐proteinuric CKD. Combined RAAS blockade as an
alternative approach to gain additive reduction in proteinuria and greater retardation
of renal function decline is shown to be associated with increased risk of hypotension,
serious hyperkalemia and acute kidney injury. In this chapter, we discuss the role of
RAAS blockade as first‐line antihypertensive therapy among people with proteinuric
and non‐proteinuric nephropathy, providing an overview of the evidence derived from
large‐scaled renal outcome trials.
Keywords: hypertension, chronic kidney disease, proteinuria, RAAS blockade,
randomized controlled trials
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1. Introduction
Hypertension in people with chronic kidney disease (CKD) is very common, often difficult to
control and represents an independent predictor of kidney injury progression to end‐stage‐
renal‐disease (ESRD) requiring dialysis [1, 2]. Apart from achieving an adequate blood pressure
(BP) control as a tool to delay nephropathy progression, the choice of the appropriate antihy‐
pertensive regimen may be another factor determining the long‐term renal prognosis in people
with CKD. In this regard, agents blocking the renin‐angiotensin‐aldosterone system (RAAS)
are considered as the antihypertensive therapy of first  choice in people with diabetic or
nondiabetic proteinuric CKD on the basis of large‐scaled outcome trials showing that these
agents are superior to the other antihypertensive drug classes in retarding kidney injury
progression over time [3, 4]. In contrast, RAAS blockade in people with non‐proteinuric CKD
is shown to confer no additional benefits toward renoprotection [4]. Furthermore, the promise
that the use of combined RAAS blockade may offer additive anti‐proteinuric and renoprotective
effects relative to monotherapy is shown to be counteracted by an excess risk of serious
hyperkalemia and acute kidney injury [5, 6].
In this chapter, we discuss the use of RAAS blockade for renoprotection in people with
proteinuric and non‐proteinuric CKD, summarizing the currently available evidence from
large‐scaled outcome trials in nephrology. We conclude with clinical practice recommenda‐
tions for the choice of the appropriate antihypertensive regimen in people with CKD and
provide directions for future research in this important area.
2. RAAS blockade in patients with proteinuric CKD
Accumulated evidence from large‐scaled randomized controlled trials (RCTs) support the
notion that inhibition of the RAAS among people with overt diabetic nephropathy confers
benefits towards slower progression of kidney injury to ESRD [4]. In the Collaborate Study
Group trial, 409 patients with insulin‐dependent type 1 diabetes and overt nephropathy
(proteinuria >500 mg/day and serum creatinine <2.5 mg/dl) were randomly assigned to receive
therapy with the angiotensin‐converting enzyme (ACE) inhibitor captopril or placebo for a
mean follow‐up of 3 years [7]. Compared with placebo, captopril treatment produced a 30%
reduction in the level of proteinuria and decreased by 50% the risk of reaching the combined
renal endpoint of all‐cause death and need for dialysis or renal transplantation [95% confidence
interval (CI) 18–70%, p < 0.01] [7]. The renoprotective effect of RAAS blockade among people
with type 2 diabetes and overt nephropathy is supported by two landmark RCTs, the Reduction
of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) [8] and
Irbesartan Diabetic Nephropathy Trial (IDNT) [9]. The RENAAL trial enrolled 1513 patients
with overt diabetic nephropathy aiming to compare the effect of the angiotensin receptor
blocker (ARB) losartan (50–100 mg daily) versus placebo, both administered on top of
conventional antihypertensive drug therapy, on a composite renal endpoint of doubling of
serum creatinine, ESRD or death [8]. Over a mean follow‐up of 3.4 years, losartan reduced by
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25% the risk of doubling of serum creatinine (P = 0.006) and by 28% the risk of ESRD requiring
dialysis relative to placebo (P = 0.002), but had no impact on mortality [8]. In the IDNT trial,
1715 hypertensive patients with overt diabetic nephropathy were randomized to receive
irbesartan (300 mg daily), amlodipine (10 mg daily) or placebo for a mean follow‐up of
2.6 years. The level of proteinuria was reduced by 33% in the irbesartan group versus 6% in
the amlodipine and 10% in the placebo groups [9]. Compared with placebo, ARB treatment
decreased by 20% the occurrence of the combined renal endpoint of doubling of serum
creatinine, ESRD or death [relative risk (RR): 0.80; 95% CI: 0.66–0.97]; ARB therapy was also
superior to the calcium channel blocker (CCB) amlodipine in improving renal outcomes (RR:
0.77; 95% CI: 0.63–0.93 for the combined renal endpoint) [9].
The renoprotective properties of ACE inhibitors and/or ARBs among patients with diabetic
nephropathy are also supported by carefully conducted meta‐analyses of RCTs. An earlier
meta‐analysis by Strippoli et al. [10] showed that compared with placebo, ACE inhibitor use
was associated with a trend towards greater reduction in the risk of doubling of serum
creatinine (RR: 0.60; 95% CI: 0.34–1.05) and incident ESRD (RR: 0.64; 95% CI: 0.40–1.03). ACE
inhibitor use was associated with 55% reduced risk of progression from micro‐ to macro‐
albuminuria (RR: 0.45; 95% CI: 0.28–0.71) and 3.42‐fold higher rate of regression from micro‐
to normoalbuminuria among patients with diabetic CKD (RR: 3.42; 95% CI: 1.95–5.99) [10].
Similarly to ACE inhibitors, the combined analysis of RCTs comparing the effect of ARBs
versus placebo on nephropathy progression associated the use of ARBs with reduced risk of
doubling of serum creatinine (RR: 0.78; 95% CI: 0.67–0.91) and ESRD incidence (RR: 0.79; 95%
CI: 0.67–0.93) [10]. The favorable effect of RAAS blockade on nephropathy progression was
confirmed in an updated meta‐analysis of 24 RCTs showing that compared with placebo, ACE
inhibitors reduced by 30% the risk of incident ESRD (RR: 0.70; 95% CI: 0.46–1.05) and by 29%
the risk of doubling of serum creatinine (RR: 0.71; 95% CI: 0.56–0.91); ARB use was associated
with 22% lower risk of ESRD incidence (RR: 0.78; 95% CI: 0.67–0.91) and 21% lower risk of
doubling of serum creatinine (RR: 0.79; 95% CI: 0.68–0.91) [11].
In accordance with the renoprotective action of RAAS blockade among people with diabetic
kidney disease, a growing body of evidence supports the notion that ACE inhibitors and ARBs
are similarly effective in delaying kidney injury progression in patients with other types of
proteinuric nephropathy. In the REIN‐2 study (Ramipril‐Efficacy‐In‐Nephropathy‐2), 352
nondiabetic patients with CKD and proteinuria of at least 1 g/day were randomized to receive
double‐blind therapy with ramipril (5 mg daily) or placebo in addition to conventional
antihypertensive therapy targeted at achieving a diastolic BP goal of <90 mmHg [12]. The rate
of estimated glomerular filtration rate (eGFR) decline, which was the primary trial endpoint,
was significantly slower over time in ramipril‐treated patients than in placebo‐treated patients
(0.53 vs. 0.83 ml/min/1.73 m2, P = 0.03). The proportional reduction in the level of proteinuria
among ramipril‐treated patients was inversely associated with the rate of eGFR decline and
was an independent predictor of the risk of doubling of serum creatinine and incident ESRD
during follow‐up [12]. In the African American Study of Kidney Disease (AASK), 1094 African‐
American patients with hypertensive CKD (mean baseline eGFR: 45.6 ml/min/1.73 m2; mean
urinary protein excretion 0.6 g/day) were randomized to achieve goal mean arterial pressure
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102–107 mmHg or ≤92 mmHg and to initial BP‐lowering treatment with metoprolol (2.5–10 mg
daily), ramipril (2.5–10 mg daily) or amlodipine (5–10 mg daily) in a 3 × 2 factorial design [13].
Compared with metoprolol and amlodipine groups, administration of the ACE inhibitor
ramipril was associated with 22 and 38% reduction in the risk of reaching the composite renal
outcome of decrease from baseline in eGFR by 50% or greater, incident ESRD, or death,
respectively [13]. In a subsequent analysis of 224 patients with advanced stage nondiabetic
CKD (baseline serum creatinine range: 3.1–5.0 mg/dl and mean proteinuria 1.6 g/day), Hou et
al. [14] compared the effect of benazepril (20 mg daily) versus placebo on top of conventional
antihypertensive therapy on a composite renal endpoint of doubling of serum creatinine, ESRD
or death. Over a mean follow‐up of 3.4 years, the risk of reaching the above combined endpoint
was by 43% lower in the ACE inhibitor group than in the placebo group. Additional benefits
of the ACE inhibitor therapy were an associated 52% reduction in the level of proteinuria along
with a 23% slower rate of eGFR decline [14]. Additional support to the renoprotective action
of ACE inhibitors is provided by an earlier meta‐analysis of 11 RCTs conducted by Jafar et al.
[15]. In this analysis, after adjustment for patient and trial characteristics at baseline and
changes in BP and proteinuria levels during follow‐up, the use of an ACE inhibitor‐based
antihypertensive regimen was associated with 31% greater reduction in the risk of developing
ESRD (RR: 0.69; 95% CI: 0.51–0.94) and 30% decrease in the risk of doubling of serum creatinine
or ESRD (RR: 0.70; 95% CI: 0.55–0.88) in comparison with antihypertensive regimens non‐
including ACE inhibitors [15].
Post hoc analyses of the aforementioned RCTs provided evidence that the higher the level of
proteinuria at baseline the higher was the risk of nephropathy progression to ESRD [16–18].
Most importantly, achievement of an early regression of proteinuria under RAAS blockade
(i.e., in the first 6 months after drug initiation) was shown to be associated with reduced long‐
term risk of doubling of serum creatinine, ESRD incidence or death [16–18]. The notion that
drug‐induced reduction in proteinuria culminates in subsequent improvement in renal
outcomes is further supported by a recent meta‐regression analysis of 21 RCTs involving a
total of 78,342 patients and 4843 incident ESRD events [19]. The placebo‐adjusted treatment
effect on proteinuria significantly correlated with the treatment effect on ESRD incidence, since
each 30% of drug‐induced reduction in the level of proteinuria was associated with a 23.7%
reduced risk of subsequent kidney injury progression to ESRD (95% CI: 11.4–34.2%, P = 0.001)
[19]. Taken together, the above data support the notion that regression of proteinuria is a major
target of therapy in order to delay nephropathy progression in patients with both diabetic and
nondiabetic proteinuric CKD.
3. RAAS blockade in patients with non-proteinuric nephropathy
Unlike the well‐documented benefits of RAAS inhibition among patients with proteinuric
CKD, either diabetic or nondiabetic, it remains largely uncertain whether ACE inhibitors and/
or ARBs carry with them a similarly beneficial effect in slowing nephropathy progression
among patients with non‐proteinuric CKD. This issue is of major clinical relevance, given the
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fact that high albuminuria or overt proteinuria is present only in a small proportion of the
overall CKD population, whereas the vast majority of people with CKD have normoalbumi‐
nuria or microalbuminuria [20–22]. For example, the prevalence of CKD among individuals
with age >70 years is estimated to be around 40%, but proteinuria is present in approximately
5% of elderly CKD patients. The prevalence of CKD in the general hypertensive population is
estimated to be around 15% (ranging up to 30% in those aged >65 years), but again <5% of
hypertensives with CKD exhibit macroalbuminuria [20–22]. Regardless of its high clinical
significance, there are no data from properly designed RCTs to evaluate the effect of RAAS
blockade on “hard” renal outcomes in patients with non‐proteinuric nephropathy. The
currently available evidence on this issue is derived mainly from secondary analyses of major
cardiovascular outcome trials.
The first trial to evaluate the issue of renoprotection with RAAS blockade in patients with non‐
proteinuric CKD was the appropriate blood pressure control in diabetes (ABCD) [23]. This trial
enrolled 470 patients with hypertension and type 2 diabetes, of whom only 18% had overt
nephropathy (i.e., macro‐albuminuria and/or impaired renal function). Study participants
were randomly assigned to nisoldipine or enalapril and intensive or moderate BP control in a
2 × 2 factorial design. The rate of change in creatinine clearance over a 5.3‐year‐long follow‐up
was no different between the enalapril and nisoldipine groups [23]. However, the most definite
renal endpoint of incident ESRD requiring dialysis was not evaluated in the ABCD study;
accordingly, this study cannot provide direct evidence on whether the enalapril‐induced
reduction in the level of proteinuria would be translated into a slower kidney injury progres‐
sion in a population predominantly without overt diabetic nephropathy.
The absence of additive renal benefits under RAAS blockade among patients with non‐
proteinuric CKD is further supported by a secondary analysis of the Antihypertensive and
Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [24]. This trial enrolled
33,000 hypertensive patients with an age of 55 years or higher and at least one additional risk
factor for ischemic heart disease. The exclusion criteria included a serum creatinine >2 mg/dl
and therapy with an ACE inhibitor for underlying CKD prior to the study enrolment. Although
actual measurements of the level of albuminuria were not included in the protocol procedures,
it is reasonable to hypothesize that participants in the ALLHAT trial were mainly hypertensives
without high albuminuria. Incidence of ESRD or >50% reduction in eGFR during follow‐up,
which was the primary composite renal endpoint of this secondary analysis, was no different
between amlodipine‐treated and chlorothalidone‐treated participants (RR: 1.12; 95% CI: 0.89–
1.40) [24]. Similarly, the ACE inhibitor lisinopril was not superior to chlorothalidone in
reducing the incidence of ESRD or >50% reduction in eGFR (RR: 1.11; 95% CI: 0.89–1.38). When
the analysis was stratified according to the level of eGFR at baseline, lisinopril therapy was not
associated with a reduced incidence of ESRD relative to chlorthalidone in the subgroups of
patients with baseline eGFR of 60–89 ml/min/1.73 m2 (RR: 1.34; 95% CI: 0.87–2.06) as well as in
those with baseline eGFR <60 ml/min/1.73 m2 (RR: 0.98; 95% CI: 0.73–1.31) [24]. In addition, at
4 years of follow‐up, eGFR was 3–6 ml/min/1.73 m2 higher in amlodipine‐treated than in
chlorothalidone‐treated participants, depending on baseline eGFR stratum. The results of the
ALLHAT come in sharp contrast to the clear renoprotective effect of RAAS blockade seen in
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trials involving patients with overt diabetic nephropathy (i.e., the aforementioned IDNT). This
discrepancy is possibly explained by the different characteristics of patients included in the
ALLHAT trial. It is reasonable to hypothesize that the absence of renoprotection with lisinopril
therapy and the better retardation of eGFR over time in amlodipine‐treated participants was
possibly due to the fact that patients enrolled in the ALLHAT were more likely to suffer from
ischemic rather than proteinuric nephropathy.
Additional support to for the notion that RAAS blockade is not associated with greater
renoprotection in comparison to other antihypertensive drug classes among patients with non‐
proteinuric CKD was provided by the renal outcomes of Avoiding Cardiovascular Events
through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH
trial) [25]. ACCOMPLISH randomized 11,506 hypertensive patients at high cardiovascular risk
to receive combination therapy with benazepril plus amlodipine or benazepril plus hydro‐
chlorothiazide. The clear benefit of the benazepril/amlodipine combination in reducing
cardiovascular morbidity and mortality led to the premature termination of the ACCOM‐
PLISH trial. Similarly to the cardiovascular benefit, the analysis of the renal outcomes showed
the benazepril/amlodipine combination was associated with a slower annual rate of eGFR
decline in comparison with the benazepril/hydrochlorothiazide combination (−0.88 vs.
−4.22 mL/min/1.73 m2 per year), despite the fact that proteinuria was less effectively reduced
in patients receiving the ACE inhibitor/CCB combination [25]. Most importantly, compared
with the benazepril/hydrochlorothiazide combination, the ACE inhibitor/CCB combination
reduced by 48% the incidence of composite renal endpoint of doubling of serum creatinine or
ESRD requiring dialysis [hazard ratio (HR): 0.48; 95% CI: 0.41–0.65] and by 27% the risk of
doubling serum creatinine, need for dialysis or death (HR: 0.73; 95% CI: 0.64–0.84) [25]. The
superiority of the ACE inhibitor/CCB combination in delaying the kidney injury progression
despite its less pronounced anti‐proteinuric effect could be once again explained by the
characteristics of the patients participating in the ACCOMPLISH trial. ACCOMPLISH
participants were predominantly older than 65 years, had preserved renal function at baseline
(mean baseline eGFR of 79 mL/min/1.73 m2) and macro‐albuminuria was present in only 5%
of study participants. Accordingly, it seems reasonable that patients with such clinical
characteristics are less likely to benefit from a therapeutic strategy targeting on proteinuria
remission; in contrast, these patients are prone to acute kidney injury due to dehydration and
hypotension.
4. Dual RAAS blockade
Combining an ACE inhibitor with an ARB was suggested as an additional therapeutic tool
aiming to enhance the anti‐proteinuric effect of single RAAS blockade, generating the hypoth‐
esis that this manoeuvre would be translated into a more effective delay in nephropathy
progression [4]. Although small RCTs showed an additive effect on proteinuria with combined
RAAS blockade relative to mono‐therapy [26, 27], large‐scaled RCTs evaluating “hard” renal
endpoints showed that the use of ACE inhibitors and ARBs in combination is associated with
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increased incidence of hypotension, hyperkalemia and acute kidney injury requiring support
with dialysis [5, 6, 28, 29].
In the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial
(ONTARGET), 25,620 patients with established cardiovascular disease or high‐risk diabetes
were randomly assigned to receive double‐blind therapy with ramipril (10 mg daily), telmi‐
sartan (80 mg daily) or both drugs in combination for a median follow‐up of 56 months [6].
Compared with mono‐therapy, dual RAAS blockade was associated with a 24% higher risk of
dialysis or doubling of serum creatinine [hazard ratio (HR): 1.24; 95% CI: 1.01–1.51]. Excess
need for dialysis in the combination group was predominantly due to episodes of acute kidney
injury, possibly attributable to the higher incidence of hypotension and hyperkalemia among
patients treated aggressively with dual RAAS blockade [6]. In the Aliskiren Trial in Type 2
Diabetes Using Cardiorenal Endpoints (ALTITUDE trial), 8561 type 2 diabetic patients with
CKD, cardiovascular disease or both were randomized to receive the direct renin inhibitor
aliskiren (300 mg daily) or placebo on top of background therapy with an ACE inhibitor or ARB
[30]. The ALTITUDE trial was prematurely terminated due to excess risk of hypotension (12.1
vs. 8.3%, p < 0.001) and hyperkalemia (11.2 vs. 7.2%, p < 0.001) in the combination group [30].
Another large‐scaled RCT investigating the potential additive renoprotective effect of dual
RAAS blockade was stopped early owing to safety concerns. This was the VA‐NEPHRON‐D
(Veteran’s Administration Nephron‐Diabetes Trial), in which 1448 type 2 diabetic patients with
overt nephropathy (i.e., urinary albumin to creatinine ratio >300 mg/g and eGFR ranging from
30 to 89.9 ml/min/1.73 m2) already treated with the ARB losartan (100 mg daily) were random‐
ized to receive add‐on therapy with the ACE inhibitor lisinopril (10–40 mg daily) or matching
placebo [5]. Once again, compared with monotherapy, combination therapy was associated
with 70% excess risk of acute kidney injury (HR: 1.70; 95% CI: 1.3–2.2) and 2.8‐fold elevated
risk of serious hyperkalemia (HR: 2.8; 95% CI: 1.8–4.3). At the time of this interim analysis, a
trend toward a benefit of dual RAAS blockade with respect to the secondary trial endpoint of
first occurrence of a decline in eGFR ≥30 ml/min/1.73 m2 or ESRD was noted (HR: 0.78; 95% CI:
0.58–1.05, P = 0.10); however, this tendency toward slower renal function decline was not
sustained over time [5]. The above data suggest that even in patients with typical diabetic
nephropathy and macro‐albuminuria, any potential long‐term renoprotective action of
combined RAAS inhibition is counteracted by excess risk of serious adverse events, including
hypotension, hyperkalemia and acute renal injury requiring acute dialysis.
Addition of mineralocorticoid‐receptor‐antagonists (MRAs) might provide renal benefits in
patients with proteinuric CKD that potentially extend over and above the renoprotection
provided by ACE inhibitors and/or ARBs alone [31, 32]. Add‐on MRA therapy was proposed
as an alternative option on the basis of data suggesting that conventional therapy with ACE
inhibitors and ARBs cannot produce sustained prolonged lowering of plasma aldosterone
levels, the so‐called aldosterone breakthrough phenomenon. An earlier meta‐analysis of 11
RCTs (including 991 patients with proteinuric CKD) showed that compared with placebo, add‐
on MRA therapy on top of background treatment with ACE inhibitors or ARBs was associated
with a significant additive reduction in proteinuria [weighted mean difference (WMD): −0.8 g/
day; 95% CI: −1.27 to −0.33 g/day]. This anti‐proteinuric effect, however, was not accompanied
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by a slower decline in eGFR (WMD: −0.70 ml/min/1.73 m2; 95% CI: −4.73 to 3.34 ml/min/
1.73 m2), whereas add‐on MRA therapy was also associated with a significantly 3.06 times
higher risk of developing hyperkalemia (pooled RR: 3.06; 95% CI: 1.26–7.41) [33]. A subsequent
updated meta‐analysis of 27 RCTs (including 1549 participants) confirmed in a larger frame of
data that add‐on MRA therapy offers an additive reduction in proteinuria [standardized mean
difference (SMD): −0.61; 95% CI: −1.08 to −0.13], but MRA use aggravated the risk of hyperka‐
lemia and gynecomastia [34]. In the albescence of properly designed RCTs evaluating the effect
of add‐on MRA therapy on nephropathy progression, the wide use of this therapeutic
approach in people with proteinuric CKD is not recommended.
A newly introduced, selective, nonsteroidal MRA‐named finerenone offers the opportunity
for similarly effective anti‐proteinuric action as compared with established steroidal MRAs
(i.e., spironolactone and eplerenone), having also the advantage of causing less frequently
clinically significant hyperkalemia [35]. The efficacy and safety of finerenone among patients
with diabetic nephropathy was tested in the recent phase 2b ARTS‐DN study (mineralocorti‐
coid receptor antagonist tolerability study–diabetic nephropathy) [36], in which 821 diabetic
patients with high or very high albuminuria already treated with an ACE inhibitor or an ARB
were randomly assigned to double‐blind therapy with finerenone (1.25 up to 20 mg once daily)
or matching placebo for 3 months. Finerenone dose‐dependently reduced albuminuria up to
33 and 38% in the 15 and 20 mg groups with only small increases in serum potassium
(+0.17 ± 0.46 and +0.23 ± 0.37, respectively) [36]. The incidence of hyperkalemia was 4.1 and
2.6%, respectively, and not significantly different from placebo. These results suggest that
finerenone may be an effective and safer approach for renoprotection in proteinuric CKD.
Properly designed RCTs are warranted to fully elucidate the effect of finerenone on “hard”
renal endpoints.
Recent RCTs have provided evidence that the novel oral potassium‐binding resins patiromer
and sodium zirconium cyclosilicate can effectively normalize elevated serum potassium and
maintain in the long‐term the potassium levels within the normal range in hyperkalemic
patients with CKD already treated with RAAS blockers [37–39]. These emerging potassium‐
lowering therapies offer promise that the reduction in the risk of drug‐induced hyperkalemia
may facilitate the administration of RAAS blockade at adequate doses and enhance the
cardiovascular and renal protection provided by these agents in people with proteinuric
CKD [29].
5. Conclusion
Choice of the appropriate antihypertensive regimen in people with CKD should be individu‐
alized according to the patient clinical characteristics, with proteinuria being an important
factor that needs to be taken into consideration. Among people with diabetic or nondiabetic
proteinuric nephropathy, large‐scaled outcome trials provided solid evidence that ACE
inhibitors and/or ARBs reduce the level of proteinuria and this anti‐proteinuric action is
subsequently translated into slower nephropathy progression to ESRD requiring dialysis. In
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contrast, there is no “hard” evidence to support the use of RAAS blockers for renoprotection
among elderly patients with preserved or mildly impaired renal function as well as in those
with non‐proteinuric CKD. The use of ACE inhibitors and ARBs in combination as an approach
to achieve additive renal benefits relative to monotherapy is contraindicated in light of
evidence suggesting that dual RAAS blockade is associated with increased risk of hypotension,
serious hyperkalemia and acute kidney injury. Novel potassium‐lowering therapies are shown
to effective compensate the hyperkalemia risk associated with RAAS blockade use in people
with CKD, offering promise for more adequate therapy and greater renal and cardiovascular
risk protection in the future.
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